The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 1 study of biweekly (Q2W) anti-EGFR monoclonal antibody (mAb) mixture Sym004 in patients (pts) with metastatic colorectal cancer (mCRC) resistant to previous anti-EGFR treatment.
Guillem Argilés
No relevant relationships to disclose
Rodrigo Dienstmann
No relevant relationships to disclose
Marta Benavent Viñuales
No relevant relationships to disclose
Andres Cervantes
No relevant relationships to disclose
Susana Rosello Keranen
No relevant relationships to disclose
Ulla H. Hansen
Employment or Leadership Position - Symphogen
Niels Jorgen Ostergaard Skartved
Employment or Leadership Position - Symphogen
Ivan David Horak
Employment or Leadership Position - Symphogen
Stephan Braun
Employment or Leadership Position - Symphogen
Rocio Garcia Carbonero
No relevant relationships to disclose